10 Million Unique Reactions to be Further Integrated into Researcher's
AMSTERDAM, March 6 /CNW/ - Elsevier, the leading global publisher of
scientific, technical and medical information, today announced the acquisition
through its subsidiary MDL Information Systems GmbH, of the Beilstein
Database, the world's largest compilation of chemical facts and the premier
database in the field of organic chemistry.
Elsevier has been exclusively involved in both the production and
marketing of the Beilstein Database under a partnership agreement since 1998.
Since then, Elsevier has added or updated close to 5 million compounds to the
database and has helped to build a strong and established customer base in
both the corporate pharmaceutical and academic sectors. As a result of the
agreement announced today, Elsevier will assume ownership and acquire the
rights to the Beilstein Database.
The Beilstein Database covers organic chemistry from 1771 to date. It
contains over 9.8 million compounds, 10 million reactions (making it the
world's largest reaction database) and 320 million experimental data on
chemical properties. It also contains over 900,000 original author abstracts
from 1980-present, as well as pharmacological and ecotoxicological data
describing the bioactivity of organic chemicals.
"This will open a new chapter for the Beilstein-Institut," noted Dr.
Martin G. Hicks, Director of the Beilstein-Institut, "We look forward to
further developing diverse activities including innovative software and
journals such as the Beilstein Journal of Organic Chemistry."
"Acquiring the Beilstein Database, with its great legacy and contribution
to science, is a natural opportunity and fit for Elsevier," said Herman van
Campenhout, Chief Executive Officer, Science and Technology, Elsevier. "As one
of the world's most significant scientific resources, it is especially
valuable for our pharmaceutical industry customers working in the area of drug
Elsevier has already pioneered closer integration between chemical
structure data and text information. For example via the Crossfire and
DiscoveryGate interfaces, customers already enjoy seamless linking between
Scopus, Elsevier's highly acclaimed abstract & indexing database, and the
chemical reactions and compounds in the Beilstein Database.
Michiel Kolman, Managing Director, Elsevier MDL in Frankfurt, where the
Beilstein database is produced, stated, "We are very excited about the
opportunities to bring even further efficiencies to the researcher's workflow
by applying innovative approaches to integration between different data
The Beilstein-Institut is a non-profit foundation and pursues its mission
for the advancement of chemical sciences particularly through information and
communication. The Beilstein-Institut is owner of the Beilstein Handbook of
Organic Chemistry, the MedPhyt medicinal plants database, and software, such
as, the Beilstein Chemical Toolkit (BCT) and Structure Editor, and the Autonom
chemical nomenclature program. The Beilstein Journal of Organic Chemistry
(BJOC); a high quality, fully refereed journal, is published as a free access
online journal www.beilstein-journals.org/bjoc.
The Beilstein-Institut is planning to extend its activities in the above
areas by increasing the functionality, content and number of products; where
possible making them freely available to the scientific community. Free access
to the proceedings of the Beilstein-Institut hosted symposia is available on
About MDL Information Systems GmbH and Elsevier MDL
MDL Information Systems GmbH and Elsevier MDL provide informatics,
database and workflow solutions that accelerate successful life sciences R&D
by improving the speed and quality of scientists' decision making. Researchers
around the world depend on Elsevier MDL and MDL Information Systems GmbH for
innovative and reliable discovery informatics software solutions and services
augmented by 400 Elsevier chemistry and life sciences journals and related
products. For more information, visit www.mdl.com.
Elsevier is a world-leading publisher of scientific, technical and
medical information products and services. Working in partnership with the
global science and health communities, Elsevier's 7,000 employees in over 70
offices worldwide publish more than 2,000 journals and 1,900 new books per
year, in addition to offering a suite of innovative electronic products, such
as ScienceDirect (http://www.sciencedirect.com/), MD Consult
(http://www.mdconsult.com/), Scopus (http://www.info.scopus.com/),
bibliographic databases, and online reference works.
Elsevier (http://www.elsevier.com/) is a global business headquartered in
Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of Reed
Elsevier Group plc (http://www.reedelsevier.com/), a world-leading publisher
and information provider. Operating in the science and medical, legal,
education and business-to-business sectors, Reed Elsevier provides
high-quality and flexible information solutions to users, with increasing
emphasis on the Internet as a means of delivery. Reed Elsevier's ticker
symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL
(New York Stock Exchange).
For further information:
For further information: Media Contacts: Beilstein-Institut, Tel: +49
(0) 69-716732-0, Email: firstname.lastname@example.org; Elsevier, Shira
Tabachnikoff, Director Corporate Relations, Tel.: +31 20 485 2736, Email: